Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ensoma logo — The future of medicine lies within us.

Ensoma

The future of medicine lies within us.

Founded 2019 United States Boston, United States 51 employees Total: $258.00M Biotechnology, Health and Wellness +1

General Information

Company Name Ensoma
Founded Year 2019
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 51
Industries Biotechnology, Health and Wellness, Life Sciences
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Ensoma. To contact Ensoma, visit ensoma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ensoma compare?

A PDF of Ensoma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ensoma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ensoma

Ensoma, established in 2019, is pioneering a transformative approach in the Biotechnology, Health and Wellness, and Life Sciences sectors. Operating from the United States, Ensoma focuses on developing one-time in vivo treatments that aim to precisely engineer blood and immune cells to combat diseases intrinsically.

With a compelling vision encapsulated by the slogan, "The future of medicine lies within us.", Ensoma endeavors to push the boundaries of genomic medicine, offering treatments that are as adaptable and precise as the body's own cells. Their innovative approach seeks to deliver a versatile and off-the-shelf solution to patients worldwide.

The company's latest financial milestone involves securing a significant $53.00M in a Late VC investment round on 01 September 2025. This round was backed by esteemed investors such as F-Prime Capital, 5AM Ventures, Bill & Melinda Gates Foundation, among others, reflecting strong confidence in Ensoma's potential to redefine the future landscape of medicine.

Business keywords: genomic medicine, in vivo treatments, gene modification, immune cell engineering, blood cell engineering, Engenious vectors, next-generation therapies, one-time treatments, non-myeloablative conditioning, outpatient healthcare, off-the-shelf biologics, rare disease treatment, precision medicine, genetic engineering

Services & Products

In Vivo Hematopoietic Stem Cell Engineering
Gene Therapy Development
Delivery System for Genetic Modifications

Target Customers

Patients with Hematologic Disorders Healthcare Providers Pharmaceutical Researchers Biotech Investors

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $53.00M 14
F-Prime Capital 5AM Ventures Bill & Melinda Gates Foundation
F-Prime Capital, 5AM Ventures +12
01 Sep 2025
Series B $50.00M 4
Delos Capital Kite Pharma SymBiosis
Delos Capital, Kite Pharma +2
01 May 2023
Series B $85.00M 14
F-Prime Capital 5AM Ventures Mirae Asset
F-Prime Capital, 5AM Ventures +12
01 Jan 2023
Series A $70.00M 10
F-Prime Capital 5AM Ventures Alexandria Venture Investments
F-Prime Capital, 5AM Ventures +8
01 Feb 2021
Spinout Undisclosed 1
University of Washington
01 Jan 2019

Ensoma Alternatives & Competitors

View All Alternatives
Ensoma vs
Thymmune Therapeutics
Thymmune Therapeutics United States

Biotech firm developing thymic cell therapies to restore immune function using machine learning

Seed
26 employees
Biotechnology, Health and Wellness
Compare Ensoma vs Thymmune Therapeutics
Ensoma vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Compare Ensoma vs Modalis Therapeutics
Ensoma vs
Capstan Therapeutics
Capstan Therapeutics

Advancing cell engineering to develop therapeutics for a broad range of diseases

Acquired
14 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ensoma

The future of medicine lies within us.
Ensoma was founded in 2019.
Ensoma is headquartered in Boston, United States.
Ensoma operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on genomic medicine, in vivo treatments, gene modification and immune cell engineering. Its customers include Patients with Hematologic Disorders, Healthcare Providers and Pharmaceutical Researchers.
Ensoma has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Ensoma has approximately 51 employees.
Ensoma has completed 5 funding rounds, raising a total of $258.00M.
Ensoma offers: In Vivo Hematopoietic Stem Cell Engineering, Gene Therapy Development, Delivery System for Genetic Modifications.
Top alternatives and competitors to Ensoma include Thymmune Therapeutics, Modalis Therapeutics, Capstan Therapeutics, Garuda Therapeutics, Guardant Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ensoma and Thymmune Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ensoma, https://bouncewatch.com/company/ensoma, updated 4 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes